Now that the books for 2021 are closed, In Vivo has crunched the numbers and can report on the best-selling pharmaceuticals last year. And what a year it was, with expectations for drug launches having been completely rewritten. Humira lost its record for peak annual drug sales, not to Keytruda as had seemed inevitable for the past couple of years, but to a product that transitioned from bench to bedside to $40bn+ dollars in under two years.
Pfizer Inc.’s Comirnaty, licensed from BioNTech SE, along with Moderna, Inc.’s mRNA COVID-19 vaccine Spikevax, capitalized on...
